ASK REDCHAT ANYTHING ABOUT KAZIA THERAPEUTICS LIMITED
Kazia Therapeutics Limited (NASDAQ: KZIA)
Listen to this Section
$10.74
-0.6650
(
-5.83% )
70.3K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Paxalisib (GDC-0084) (PI3K pathway)DetailsGlioblastoma |
Phase 2/3 |
| Paxalisib (GDC-0084) (PI3K pathway)DetailsGlioma |
Phase 2 |
| Paxalisib (GDC-0084) (PI3K pathway)Detailsprimary central nervous system lymphomas |
Phase 2 |
| EVT801DetailsSolid tumor/s, Cancer |
Phase 2 |
| Cantrixil (TRX-E-002-1)DetailsOvarian cancer |
Failed |
| Paxalisib (GDC-0084)DetailsGlioblastoma |
Phase 2/3 |
| Paxalisib (GDC-0084)DetailsGlioma |
Phase 2 |
| Paxalisib (GDC-0084)Detailsprimary central nervous system lymphomas |
Phase 2 |
Market Data
|
| Open |
$10.74 |
| Previous Close |
$11.40 |
| Volume |
70.3K |
| Market Cap |
$125.13M |
| Day Range |
$10.68 - $11.57 |
| 52 Week Range |
$4.86 - $17.40 |
| Shares Outstanding |
11.43M |
| Change % |
-5.83% |
| Net Change |
▼ -0.6650 |
| Insider Ownership |
N/A |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 1999 |
| Country | Australia |
Insider Ownership Transactions
Total Amount Purchased:
0.00
| Date |
Type |
Amount Purchased |
Purchaser |
| No records found. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 6-k |
Form 6-K |
84 |
Jun 10, 2025 |
| 6-k |
Form 6-K |
2 |
Jun 05, 2025 |